Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix–Targeted Radiopharmaceutical against Triple-Negative Breast Cancer
The 89Zr/177Lu theranostic nuclide coupling successfully identified triple negative breast cancer xenografts, and significantly extended survival of xenografted mice.
Authors
- Sebastian E. Carrasco (ORCID: https://orcid.org/0000-0002-1926-7296)
- Tara Viray
- Lukas M. Carter (ORCID: https://orcid.org/0000-0003-4848-4190)
- Domenico Ravazza (ORCID: https://orcid.org/0009-0006-5739-8090)
- Mattia Matasci (ORCID: https://orcid.org/0000-0003-4221-8852)
- Jason S Lewis
- Dario Neri
- Justin S Hachey
Institutions
- University of Siena (IT)
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Philogen (Italy) (IT)
- Philochem (Switzerland) (CH)
- École Polytechnique Fédérale de Lausanne (CH)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3354
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00